Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.66 |
| ▸ | NPY1R | P25929 | 9/20 | 0.66 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.66 |
| ▸ | NPY2R | P49146 | 5/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31729537 | 0.98 | NPY4R (0.69) | NPY4RNPY1RNPY5RNPY2R | |
| Kyotorphin SCHEMBL248289 | 0.98 | NPY4R (0.62) | NPY4RNPY1RNPY5RNPY2R | |
| D[-Arg-2]Kyotorphan Acetate SCHEMBL29780328 | 0.98 | NPY4R (0.62) | NPY4RNPY1RNPY5RNPY2R | |
| Kyotorphin SCHEMBL2889815 | 0.98 | NPY4R (0.62) | NPY4RNPY1RNPY5RNPY2R | |
| Kyotorphin SCHEMBL248288 | 0.98 | NPY4R (0.62) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL13563452 | 0.97 | NPY4R (0.67) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL31155494 | 0.97 | NPY4R (0.67) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL18951657 | 0.97 | NPY4R (0.67) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30274541 | 0.95 | NPY4R (0.63) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29637467 | 0.95 | NPY4R (0.66) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118853640-A | Carbapenem drug-resistant gene and application thereof | 郑州大学 | 2024-10-29 | — | — | CN | disclosed |
| EP-3215172-B1 | MODIFICATIONS AND USES OF CONOTOXIN PEPTIDES | KINETA CHRONIC PAIN LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-11618772-B2 | Modifications and uses of conotoxin peptides | KINETA CHRONIC PAIN, LLC | 2023-04-04 | — | — | US | disclosed |
| US-11566256-B2 | Polynucleotides and polypeptides in plants | MENDEL BIOTECHNOLOGY, INC. (US) | 2023-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11618772-B2 | Modifications and uses of conotoxin peptides | CHRNA9, CHRNA10, CHRNA7 | NPY4R 130/4885NPY1R 139/4885NPY5R 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.